内分泌治疗抵抗、激素受体阳性乳腺癌的选择：哪些靶点及何时？
Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
机构信息
Division of Medical Oncology, University of Colorado Cancer Center and University of Colorado Anschutz Medical Center, Aurora, CO.
出版信息
J Clin Oncol. 2021 Dec 10;39(35):3890-3896. doi: 10.1200/JCO.21.01910. Epub 2021 Oct 28.
PMID:34709849
Abstract
Journal of Clinical Oncology, .
摘要
临床肿瘤学期刊，.
相似文献
1
Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
J Clin Oncol. 2021 Dec 10;39(35):3890-3896. doi: 10.1200/JCO.21.01910. Epub 2021 Oct 28.
2
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
J Clin Oncol. 2020 Apr 20;38(12):1258-1267. doi: 10.1200/JCO.19.02242. Epub 2019 Oct 16.
3
Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
J Clin Oncol. 2017 Aug 10;35(23):2600-2603. doi: 10.1200/JCO.2017.72.5960. Epub 2017 Jun 29.
4
Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
J Clin Oncol. 2021 Nov 10;39(32):3535-3540. doi: 10.1200/JCO.21.01896. Epub 2021 Oct 6.
5
Late Recurrence Following Early Breast Cancer.
J Clin Oncol. 2022 May 1;40(13):1400-1406. doi: 10.1200/JCO.22.00167. Epub 2022 Mar 3.
6
Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
J Clin Oncol. 2020 Jul 10;38(20):2290-2298. doi: 10.1200/JCO.19.03036. Epub 2020 May 22.
7
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
J Clin Oncol. 2016 May 10;34(14):1573-9. doi: 10.1200/JCO.2015.65.3493. Epub 2016 Mar 7.
8
Late Breast Cancer Survivorship: Side Effects and Care Recommendations.
J Clin Oncol. 2022 May 20;40(15):1604-1610. doi: 10.1200/JCO.22.00049. Epub 2022 Feb 28.
9
Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
Clin Cancer Res. 2006 Aug 15;12(16):4790-3. doi: 10.1158/1078-0432.CCR-06-1535.
10
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
J Clin Oncol. 2017 Sep 1;35(25):2866-2870. doi: 10.1200/JCO.2017.73.9482. Epub 2017 Jun 3.
引用本文的文献
1
TSPAN1 overexpression as an indicator of poor prognosis in estrogen receptor-positive breast cancer.
Transl Cancer Res. 2024 Aug 31;13(8):4159-4171. doi: 10.21037/tcr-24-409. Epub 2024 Aug 21.
Zotero 插件